Tuberculosis hides inside our immune cells. Scientists just found two proteins that help unmask it
Tuberculosis kills more people each year than almost any other infectious disease. The bacterium survives by hiding inside the very cells meant to destroy it.
Mycobacterium tuberculosis is an expert at intracellular concealment. By taking refuge inside macrophages — the immune cells tasked with destroying pathogens — the bacterium avoids many of the body’s standard defences. CD8+ T cells, a subset of immune cells capable of inspecting the interiors of other cells, represent one route to detecting and killing infected cells. But for that to work, fragments of the bacterium must be displayed on the cell surface through a molecular platform called MR1. How that display process is regulated has been poorly understood.
A study published in eLife now identifies two proteins — synaptotagmin 1 and synaptotagmin 7 — as active promoters of MR1-mediated antigen presentation. These proteins normally regulate vesicle fusion and molecular release in cells, including in neurons during signal transmission. Their role in how immune cells display bacterial fragments at the surface is an unexpected finding with potentially significant implications.
Why TB antigens are so hard to detect
Compared to most viral infections, M. tuberculosis produces relatively few antigens — molecular signatures that the immune system can recognise as foreign. That scarcity makes it harder for the body to mount a rapid and targeted response. The MR1 pathway is one of several specialised mechanisms the immune system has evolved to handle pathogens that present limited antigen repertoires. By identifying synaptotagmin 1 and 7 as facilitators of this pathway, the researchers reveal a previously unknown layer of regulation in tuberculosis immunity.
The practical implication is that enhancing the activity of these proteins — through drugs, vaccines, or other interventions — could potentially strengthen the body’s ability to detect and eliminate TB-infected cells. Whether and how that could be translated into a therapeutic strategy requires considerably more research.
The ageing immune system and reactivation risk
The connection to longevity is indirect but meaningful. As people age, immune function declines — a process known as immunosenescence. This makes older adults more vulnerable to new tuberculosis infections, but also to reactivation of latent TB that was previously kept in check by the immune system. An estimated one quarter of the world’s population carries latent M. tuberculosis; in most cases, the infection never causes disease. Understanding how the body monitors infected cells through pathways like MR1 could help explain why that surveillance fails with age — and whether it can be reinforced.
This is fundamental science: no drug or vaccine candidate emerges directly from the study. But identifying a previously unknown regulatory mechanism in tuberculosis immunity is the kind of knowledge that redirects the field and opens new experimental avenues.